Intuitive Surgical has received FDA 510(k) clearance for its da Vinci 5 surgical system to perform a range of minimally invasive cardiac procedures, including mitral valve repair and coronary artery bypass grafting through small thoracic incisions. The clearance covers both the surgeon console and patient-side cart upgrades, marking the first time the company’s flagship robot is officially approved for these complex heart operations. Analysts estimate that this approval could open a $1.2 billion addressable market in the U.S., with over 50,000 cardiac surgeries performed annually using traditional methods that could transition to robotic assistance over time.

With more than 11,100 da Vinci systems installed worldwide, Intuitive has recorded an 18% year-over-year increase in procedures, driven in part by strong demand in North America and Europe. The company’s extensive database of over 15 million surgical cases forms the backbone for its AI-driven enhancements. Recently, the FDA granted clearance for an AI module in the Ion endoluminal system that provides real-time lesion detection during lung biopsies. Management highlights that these software upgrades carry gross margins above 80%, and recurring software service revenues now represent 12% of total revenue, underscoring the strategic shift toward software-enabled solutions.

Intuitive Surgical’s growth in China has slowed as local competitors gain traction in government tenders and manufacturers press pricing advantages. In the most recent quarter, China accounted for 9% of total procedures, down from 12% a year earlier. Local hospitals have reported preferring da Vinci’s precision, but procurement committees are increasingly influenced by price concessions and ‘home-grown’ quotas. Company executives warned that 2026 could see the launch of several domestically produced robots with capabilities closely mirroring da Vinci’s core functions, potentially eroding share unless Intuitive responds with targeted service bundles and financing incentives.